Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Atezolizumab + Chemotherapy in ES-SCLC
NCT04422210Phase 1Terminated
- Sponsor
- Roche
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of venetoclax in small cell lung cancer (SCLC) (8 arms), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events and Overall Response Rate up to 24 months. Started Sep 2020; status: terminated.
02
Drugs
venetoclax
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04422210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04422210.